IMA401 + pembrolizumab

IMA401 + pembrolizumab is an investigational combination therapy evaluated for patients with recurrent and/or refractory solid tumors. IMA401 is a bispecific T cell engaging receptor molecule (TCER) designed to target cancer cells expressing the antigens MAGEA4 and MAGEA8, redirecting T cells to kill these tumor cells. Pembrolizumab is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to reactivate T cell-mediated antitumor immunity. The combination aims to harness IMA401’s specific T-cell redirection and pembrolizumab’s checkpoint blockade to enhance anti-tumor responses, particularly in tumors with high MAGEA4/8 expression such as head and neck, lung, and bladder cancers. IMA401 is developed by Immatics. Pembrolizumab is developed and manufactured by Merck. The combination is in Phase 1 clinical evaluation for safety, tolerability, initial efficacy, and dose optimization[1][2][3].

Other names

IMA401 TCERIMA-401 TCERIMA 401 TCER